Acuta Capital Partners as of Sept. 30, 2021
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 47 positions in its portfolio as reported in the September 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Aadi Bioscience (AADI) | 15.8 | $45M | 1.5M | 29.37 | |
| Vistagen Therapeutics Com New | 11.3 | $32M | 12M | 2.74 | |
| Iveric Bio | 6.5 | $18M | 1.1M | 16.24 | |
| Celldex Therapeutics Com New (CLDX) | 6.4 | $18M | 338k | 53.99 | |
| Bellus Health Com New | 4.3 | $12M | 2.0M | 6.14 | |
| Iovance Biotherapeutics (IOVA) | 3.3 | $9.2M | 375k | 24.66 | |
| Fulcrum Therapeutics (FULC) | 3.2 | $9.1M | 323k | 28.21 | |
| Gh Research Ordinary Shares (GHRS) | 3.1 | $8.7M | 393k | 22.06 | |
| Bcls Acquisition Corp Com Cl A | 3.0 | $8.4M | 843k | 9.96 | |
| Clearside Biomedical (CLSD) | 2.8 | $7.9M | 1.3M | 6.00 | |
| Arrowhead Pharmaceuticals (ARWR) | 2.7 | $7.6M | 122k | 62.43 | |
| Apricus Biosciences | 2.4 | $6.9M | 2.9M | 2.41 | |
| Cyteir Therapeutics | 2.4 | $6.9M | 392k | 17.55 | |
| Xenon Pharmaceuticals (XENE) | 2.3 | $6.4M | 417k | 15.28 | |
| Verastem | 2.2 | $6.2M | 2.0M | 3.08 | |
| Jiya Acquisition Corp Com Cl A | 1.9 | $5.5M | 563k | 9.75 | |
| Kura Oncology (KURA) | 1.9 | $5.5M | 292k | 18.73 | |
| Selecta Biosciences | 1.5 | $4.3M | 1.0M | 4.16 | |
| Vincerx Pharma Com New (VINC) | 1.5 | $4.2M | 260k | 16.17 | |
| Olema Pharmaceuticals (OLMA) | 1.5 | $4.1M | 151k | 27.56 | |
| Syndax Pharmaceuticals (SNDX) | 1.4 | $3.9M | 206k | 19.11 | |
| Health Sciences Acq Corp 2 Ord Shs | 1.4 | $3.9M | 393k | 9.89 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 1.4 | $3.9M | 370k | 10.42 | |
| Krystal Biotech (KRYS) | 1.3 | $3.8M | 73k | 52.21 | |
| Cabaletta Bio (CABA) | 1.3 | $3.7M | 303k | 12.16 | |
| Athira Pharma (ATHA) | 1.0 | $2.8M | 297k | 9.38 | |
| Rain Therapeutics | 1.0 | $2.7M | 183k | 14.96 | |
| Gossamer Bio (GOSS) | 1.0 | $2.7M | 215k | 12.57 | |
| Merus N V (MRUS) | 0.9 | $2.7M | 122k | 22.00 | |
| Aclaris Therapeutics (ACRS) | 0.9 | $2.5M | 141k | 18.00 | |
| Apellis Pharmaceuticals (APLS) | 0.9 | $2.5M | 76k | 32.95 | |
| Avadel Pharmaceuticals Sponsored Adr Call Option | 0.9 | $2.5M | 250k | 9.80 | |
| Miragen Therapeutics (VRDN) | 0.8 | $2.2M | 136k | 16.45 | |
| Allakos (ALLK) | 0.7 | $1.9M | 18k | 105.89 | |
| Reata Pharmaceuticals Cl A | 0.6 | $1.8M | 18k | 100.63 | |
| Altimmune Com New (ALT) | 0.6 | $1.7M | 150k | 11.31 | |
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.6 | $1.6M | 38k | 41.59 | |
| Catalyst Biosciences Com New | 0.5 | $1.5M | 365k | 4.11 | |
| Avidity Biosciences Ord (RNA) | 0.5 | $1.5M | 60k | 24.63 | |
| Astria Therapeutics | 0.5 | $1.4M | 157k | 8.84 | |
| Chimerix (CMRX) | 0.5 | $1.3M | 210k | 6.19 | |
| Cymabay Therapeutics | 0.4 | $1.1M | 302k | 3.65 | |
| C4 Therapeutics Stk Com Stk (CCCC) | 0.3 | $938k | 21k | 44.67 | |
| Elanco Animal Health (ELAN) | 0.3 | $925k | 29k | 31.90 | |
| United Therapeutics Corporation (UTHR) | 0.2 | $554k | 3.0k | 184.67 | |
| Novavax Com New (NVAX) | 0.2 | $480k | 2.3k | 207.34 | |
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.1 | $242k | 91k | 2.66 |
